细胞角蛋白19片段、癌胚抗原和神经元特异性烯醇化酶联合检测对晚期非小细胞肺癌患者的预后价值
Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
作者信息
Barlési Fabrice, Gimenez Céline, Torre Jean-Philippe, Doddoli Christophe, Mancini Julien, Greillier Laurent, Roux François, Kleisbauer Jean-Pierre
机构信息
Faculty of Medicine, Université de la méditerranée, Assistance Publique Hôpitaux de Marseille, Service d'Oncologie Thoracique, Marseille, Cedex 09, France.
出版信息
Respir Med. 2004 Apr;98(4):357-62. doi: 10.1016/j.rmed.2003.11.003.
OBJECTIVE
To assess the value of Cyfra 21-1, carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) combined, all three together as prognostic factors in advanced stage non-small cell lung cancer (NSCLC) patients.
PATIENTS AND METHODS
Serum samples from untreated NSCLC patients were prospectively collected. All assays were performed using commercial kits blind to clinical information. Serum levels of CEA, NSE and Cyfra 21-1 higher than 10, 13 and 3.5 ng/ml, respectively, were considered as elevated.
RESULTS
264 patients (men, 87%), with Performans Status (PS) of 0/1 in 80% and stage IV disease in 65% were studied. Cyfra 21-1, CEA and NSE were elevated in 52.5%, 41.8% and 33.2% of patients, respectively. Median survival was 9 months (range, 1-77). Cyfra 21-1, age, PS, stage as well as the combination of the three markers together correlated with prognosis in univariate analysis. Multivariate analysis demonstrated that age > or = 65 years (HR = 1.3 [1.02-1.70], p = 0.03), PS 2 (HR = 4.3 [3.13-6.11], p < 0.0001), Cyfra 21-1 > or = 3.5 ng/ml (HR = 1.3 [1.06-1.78], p = 0.01) and the combination of the three markers (HR = 1.06 [1.009-1.13], p = 0.02) remained prognostic determinants.
CONCLUSION
Combining Cyfra 21-1, NSE and CEA correlated with prognosis in a significant and independent manner.
目的
评估细胞角蛋白19片段（Cyfra 21-1）、癌胚抗原（CEA）和神经元特异性烯醇化酶（NSE）联合检测作为晚期非小细胞肺癌（NSCLC）患者预后因素的价值。
患者与方法
前瞻性收集未经治疗的NSCLC患者的血清样本。所有检测均使用对临床信息保密的商业试剂盒进行。CEA、NSE和Cyfra 21-1血清水平分别高于10、13和3.5 ng/ml被视为升高。
结果
研究了264例患者（男性占87%），80%的患者体力状况（PS）为0/1，65%的患者为IV期疾病。Cyfra 21-1、CEA和NSE分别在52.5%、41.8%和33.2%的患者中升高。中位生存期为9个月（范围1-77个月）。单因素分析显示，Cyfra 21-1、年龄、PS、分期以及这三种标志物的联合检测与预后相关。多因素分析表明，年龄≥65岁（HR = 1.3 [1.02-1.70]，p = 0.03）、PS为2（HR = 4.3 [3.13-6.11]，p < 0.0001）、Cyfra 21-1≥3.5 ng/ml（HR = 1.3 [1.06-1.78]，p = 0.01）以及这三种标志物的联合检测（HR = 1.06 [1.009-1.13]，p = 0.02）仍然是预后的决定因素。
结论
Cyfra 21-1、NSE和CEA联合检测与预后显著且独立相关。
Zotero 插件